Issue link: https://www.e-digitaleditions.com/i/1519174
16 Pharmaceutical Technology ® Innovations in mRNA eBook April 2024 PharmTech.com UPSTRE AM PROCESSING nanoparticle formulation, so advances in new deliv- ery technologies, which would eliminate the use of large volumes of organic solvent, would have a posi- tive impact on reduction of waste. This is the part of the process that presents the most challenges from a waste and safety infrastructure perspective," she concludes. Patterson points again to process optimization. "By fine-tuning reaction conditions, such as temperature, pressure, and reaction time, it is possible to minimize the need for excessive solvent volumes. Employing innovative techniques, such as continuous f low pro- cessing or solid-phase synthesis, can also help limit solvent requirements." Patterson goes on further to point out that the "the chemistries that are currently used to produce oli- gonucleotides using phosphoramidites require sig- nificant quantities of organic solvents. Instead, sev- eral groups have been researching the possibility of synthesizing oligonucleotides with various enzymes. Initial studies have shown there may be a possibility that at least some oligonucleotides could be synthe- sized with enzymes in aqueous, non-toxic solutions. This is an alternative oligonucleotide synthesis tech- nology that certainly has promise in reducing solvent consumption if it can be put into practice." References 1. CARsgen. CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine. Press Release. Aug. 21, 2023. 2. Pfizer. Pfizer and Beam Enter Exclusive Multi-Tar- get Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases. Press Release. Jan. 10, 2022. 3. BioNTech. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Thera- peutics for Solid Tumors, BioNTech. Press Release. April 3, 2023. 4. Blakney, A.; Webb, C.; Bathula, N. Current Status and Future Perspectives on MRNA Drug Manufac- turing. Mol Pharm. 2022 19(4). doi: 10.1021/acs. molpharmaceut.2c00010. 5. Smith, K. Presentation. Bio Process International US West, Feb. 27-March 2, 2023. ■ The Rush for Quality Data and the Means to Protect It In this episode of Drug Digest, industry experts discuss why data is the biopharma industry's most valuable asset today. The discussion also delves into the means by which the indus- try as a whole is learning to upgrade data integrity practices to better protect their data and the use of innovative technol- ogies, such as advanced graph technologies, to better shape the drug discovery and development process. Drug Digest is a tech talk video series with the Pharmaceutical Technology ® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products. Nathalie Batoux, Product Manager, Research Innovation, IDBS Jeremy Grignard, Data & Research Scientist, Servier For more videos, visit PharmTech.com! Thierry Dorval Head of Data Science & Data Management Servier